UGT1A9 -275T>A/-2152C>T Polymorphisms Correlate With Low MPA Exposure and Acute Rejection in MMF/Tacrolimus-Treated Kidney Transplant Patients

Does the Evidence Support the Use of Mycophenolate Mofetil Therapeutic Drug Monitoring in Clinical Practice? A Systematic Review

(2009) Simon R. Knight et al.   TRANSPLANTATION

Population pharmacokinetic modelling for enterohepatic circulation of mycophenolic acid in healthy Chinese and the influence of polymorphisms in UGT1A9

(2008) Zheng Jiao et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Current target ranges of mycophenolic acid exposure and drug-related adverse events: A 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients

(2008) Dirk R.J. Kuypers et al.   CLINICAL THERAPEUTICS

Pharmacogenetic effect of the UGT polymorphisms on mycophenolate is modified by calcineurin inhibitors

(2008) L’Aurelle A. Johnson et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients

(2008) Dennis A. Hesselink et al.   Pharmacogenetics and Genomics

Comparing Mycophenolate Mofetil Regimens for de Novo Renal Transplant Recipients: The Fixed-Dose Concentration-Controlled Trial

(2008) Teun van Gelder et al.   TRANSPLANTATION